Current drug resistance testing takes 3 weeks to deliver results. There is a need for an antiviral efficacy test that delivers results as quickly as possible.

The purpose of this study is to determine the efficacy of an experimental antiviral efficacy device called SpectraPoint. If the new system works as planned, results of the test could be obtained as quickly as 24 hours. The hope is that in many cases patients would receive clinical benefit from faster data delivery to inform their treatment decisions.

 

 

This study involves one blood draw and a second visit to receive their drug resistance results.

This study will compare current phenotypic resistance tests with the experimental SpectraPoint testing device.

Study volunteers will receive free phenotypic testing and will be compensated $25 for their time and inconvenience.

 

• HIV-positive adult male or female
• Have documented previous drug resistance test with current viral load greater than 500 OR failing HAART triple therapy with viral current viral load greater than 10,000
• Not have active Hepatitis B infection

 

Enrolling
--

This ad was reviewed and approved by the AIDS Research Alliance Institutional Review Board in April, 2005.